Tesamorelin
Stabilized GHRH(1-44) analog carrying a trans-3-hexenoyl modification that resists DPP-4 cleavage. Same receptor as CJC-1295, different backbone and different stabilization strategy.
For laboratory research use only. Material is supplied as a research reference standard and is not approved by Health Canada. Protocols below are compiled from published literature and supplier documentation; they are reference information, not medical advice. Anyone with a health condition or on medication should speak to a physician first.
Before you begin
- • Lot-matched certificate and laboratory notebook
- • Calibrated pipettes, low-binding tubes and suitable PPE
- • Validated solvent, assay reagents and model-specific SOP
- • Appropriate positive, negative and vehicle controls
Required controls
- Vehicle-only negative control
- Receptor-null or antagonist condition
- Validated reference ligand
- Untreated viability control
Reported protocol
- Standard daily
- 1.0 mg to 2.0 mg daily
- Timing
- Once daily before bedtime, or on waking in a fasted state
- Route
- Subcutaneous
- Cycle length
- 8 to 12 weeks continuous
Diluent
Sterile bacteriostatic water (0.9% benzyl alcohol) for multi-withdrawal stock, or sterile water for injection where a preservative-free stock is required by the assay.
Reconstitution concentrations
Solvent volume sets the stock concentration. Lower volume gives a more concentrated stock and smaller working aliquots; higher volume gives a more dilute stock that is easier to measure accurately.
| Solvent added | Stock concentration | Per 0.1 mL | Per unit (U-100) |
|---|---|---|---|
| 1 mL | 20 mg/mL | 2 mg | 200 mcg |
| 2 mL | 10 mg/mL | 1 mg | 100 mcg |
| 3 mL | 6.67 mg/mL | 666.67 mcg | 66.67 mcg |
| 5 mL | 4 mg/mL | 400 mcg | 40 mcg |